A phase-specific drug that causes DNA strand breakage and the inhibition of type II topoisomerase, which leads to cell death.

Induction therapy for refractory childhood acute lymphoblastic leukemia.

Metabolized in the liver; excreted in urine and bile.

165 mg/m² in combination with cytosine arabinoside 300 mg/m² IV two times a week for 8 or 9 doses. Alternatively, 250 mg/m² in combination with vincristine 1.5 mg/m² IV once a week for 4 to 8 doses and prednisone 40 mg/m² PO for 28 days.